Loading...
•
Sep 30, 2020
Ironwood Pharmaceuticals Q3 2020 Earnings Report
Reported strong financial results driven by LINZESS growth and profitability.
Key Takeaways
Ironwood Pharmaceuticals reported a strong third quarter, driven by continued demand for LINZESS, which saw a 10% increase in net sales year-over-year. The company reported profitability and positive cash flow.
U.S. LINZESS net sales increased 10% year-over-year to $241 million, as reported by AbbVie.
U.S. LINZESS collaboration revenue to Ironwood increased 18% year-over-year to $100 million, resulting in 3Q 2020 total Ironwood revenue of $103 million.
3Q 2020 GAAP net income was $34 million and adjusted EBITDA was $47 million.
Expect total cost savings of approximately $95 million, excluding anticipated one-time costs, relating to discontinuation of IW-3718 and planned workforce reduction.
Forward Guidance
Ironwood increased full year 2020 financial guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...